CAMBRIDGE, Mass., March 28,
2024 /PRNewswire/ -- Nested Therapeutics, a
biotechnology company pioneering a next-generation precision
medicine platform to address hard-to-treat cancers, today announced
that preclinical data from its lead program, NST-628, will be
featured in an oral presentation in the "New Drugs on the Horizon"
series at the American Association for Cancer Research (AACR)
Annual Meeting taking place in San Diego,
California from April 5-10,
2024.
The preclinical data supports NST-628's profile as a
mechanistically novel, fully brain penetrant non-degrading
pan-RAF/MEK molecular glue that targets RAF and MEK nodes in the
RAS-MAPK pathway. Details for the presentation are listed
below.
Title: NST-628 is a Novel, Potent, Fully
Brain-Penetrant MAPK Pathway Molecular Glue that Inhibits RAS- and
RAF-Driven Cancers
Session: New Drugs on the Horizon: Part 3
Session Date and Time: Monday, April
8, 10:15-11:45 a.m. PT
Presentation Date and Time: Monday,
April 8, 10:40-10:55 a.m.
PT
Location: Ballroom 20 CD, upper level, San Diego Convention Center
Presenter: Klaus Hoeflich, Ph.D., chief scientific
officer and co-founder of Nested
About NST-628
NST-628 is a fully brain-penetrant,
mechanistically novel non-degrading molecular glue that targets
multiple nodes in the RAS/MAPK pathway. NST-628 was developed based
on Nested's proprietary structural insights of how signaling
complexes form and function in cancer and addresses common pitfalls
of other MAPK-targeted compounds, which remain unable to circumvent
the risk of resistance via signaling pathway reactivation.
Preclinical data evaluating all biomarkers relevant to
RAS/MAPK-driven cell and patient-derived models collectively
demonstrate superior anti-tumor activity, including in RAS and
central nervous system-implanted tumor models, and tolerability of
NST-628 compared to other MAPK-targeted compounds administered as
either single agents or in combination. With a half-life and
metabolic profile optimized to achieve a superior therapeutic index
on a daily dosing schedule, as well as full intrinsic blood brain
barrier penetrance, these data support NST-628's potential as a
best-in-class treatment for RAS and RAF-driven cancers.
About Nested Therapeutics
Nested Therapeutics is a
biotechnology company focused on discovering and developing novel,
targeted, small molecule precision medicine therapies for patients
with cancer by using mutation clusters to identify druggable
pockets. With a platform that utilizes insights from genomics,
computational chemistry, proteomics and AI, Nested is working to
reach untapped mutations with the potential to improve outcomes for
millions of patients. To learn more, visit www.nestedtx.com and
follow Nested Therapeutics on Twitter (@Nestedtx) and LinkedIn.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nested-therapeutics-to-present-preclinical-data-for-nst-628-a-novel-pan-rafmek-molecular-glue-in-the-new-drugs-on-the-horizon-series-at-2024-aacr-annual-meeting-302101828.html
SOURCE Nested Therapeutics Inc.